© 2003 by Oxford University Press
Journal of the National Cancer Institute, Vol. 95, No. 1, 8-9,
January 1, 2003
© 2003 Oxford University Press
NEWS |
European Groups Oppose Myriads Latest Patent on BRCA1
| The first 10% of the full text of this article appears below. |
When Gert Matthijs, Ph.D., complained to an audience of geneticists in October about an American companys monopoly in Europe involving testing for mutations in the breast cancer gene BRCA1, he apparently found sympathetic ears. Those attending the session at the American Society of Human Genetics meeting in Baltimore heard Matthijs, associate professor of human genetics at the University Hospital in Leuven, Belgium, outline the reasons behind the European discontent with several patents held by Myriad Genetics Inc., of Salt Lake City, Utah. Then members of the audience did something that surprised even Matthijs: They applauded for several minutes.
| |||||||||||
So goes round 2 in the Great European Gene Patent Dispute.
Round 1 began in October 2001, when the Paris-based Institut